Lymphoma

Regional Health is involved in lymphoma research trials. Below is more information about the purpose and who the physician (principal investigator) is for each trial. For more in-depth information on the research studies, click the blue name which will lead you to the U.S. National Institute of Health website or call (605) 755-2300.


CC-5013-NHL-008
Phase 3B Randomized Study of Lenalidomide (cc-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single Agent Maintenance versus Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone or Mantel Cell Lymphoma

PURPOSE: This Phase 3B multicenter, randomized (stratified by histology, lines of anti-lymphoma therapy and age), open label study will enroll subjects with relapsed/refractory follicular lymphoma (FL), marginal zone lymphoma (MZL) or mantle cell lymphoma (MZL). All subjects will receive 12 Cycles of lenalidomide plus rituximab induction therapy. The study is designed to compare the efficacy and safety of two maintenance regimens following induction therapy. Subjects will be randomized at study start to lenalidomide plus rituximab combination therapy (for 18 Cycles) followed by lenalidomide single-agent maintenance (to progression; Arm A, experimental) versus rituximab single-agent maintenance (for 18 Cycles; Arm B, control). The study is divided into a Screening Period, a Treatment Period (induction and maintenance), and a Follow up Period. Approximately 500 subjects are planned to be randomized.

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Michael Robinson, MD
Medical Oncology

E1412
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

PURPOSE: This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide works in treating patients with newly diagnosed stage II-IV diffuse large B cell lymphoma. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether rituximab and combination chemotherapy are more effective when given with or without lenalidomide in treating patients with diffuse large B cell lymphoma.

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Joshua Lukenbill, DO
Medical Oncology
Hematology

RU051417I
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide (R2-ICE) in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

PURPOSE: This phase I/II trial studies the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) and how well they work in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement and that has not responded to previous treatment. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as R-ICE, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lenalidomide with R-ICE may be a better treatment for patients with diffuse large B-cell lymphoma.

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Joshua Lukenbill, DO
Medical Oncology
Hematology